SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 2188674

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2188674

T-cell Engager Market Size, Share & Trends Analysis Report By Molecular Format, By Target Antigen, By Therapeutic Application, By Route of Administration, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

T-cell Engager Market Summary

The global t-cell engager market size was valued at USD 5.0 billion in 2025 and is projected to grow from USD 6.6 billion in 2026 to USD 14.5 billion by 2033, at a CAGR of 11.9% from 2026 to 2033. The market in North America dominated with a revenue share of 74.1% in 2025. Market growth is driven by the increasing adoption of immunotherapies for cancer treatment, rising demand for targeted therapies, and advancements in bispecific antibody engineering. Growing clinical research into T-cell engagers for hematological malignancies and solid tumors, along with expanding investments in oncology drug development, is further supporting market growth.

Global T-cell Engager Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global T-cell engager market on the basis of molecular format, target antigen, therapeutic application, route of administration, and region

  • Molecular Format Outlook (Revenue, USD Million, 2021 - 2033)
  • Bispecific T-Cell Engagers
  • TCR-Based T-Cell Engagers
  • Target Antigen Outlook (Revenue, USD Million, 2021 - 2033)
  • CD19
  • CD20
  • BCMA
  • GPRC5D
  • DLL3
  • Others
  • Therapeutic Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Hematological Malignancies
  • Solid Tumors
    • Small Cell Lung Cancer
    • Melanoma
    • Other Solid Tumors
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Intravenous
  • Subcutaneous
  • Other (Intraperitoneal)
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Product Code: GVR-4-68041-069-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Molecular Format Segment
      • 1.1.1.2. Target Antigen Segment
      • 1.1.1.3. Therapeutic Application Segment
      • 1.1.1.4. Route of Administration Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. List of Secondary Sources
    • 1.9.3. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Expanding clinical trials for T-cell engager therapies
      • 3.2.1.2. Growing adoption of targeted immunotherapies
      • 3.2.1.3. Increasing prevalence of cancer
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Complexities in bispecific antibody design and manufacturing
      • 3.2.2.2. High costs of drug development and clinical trials
    • 3.2.3. Market Opportunities Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Economic landscape
      • 3.3.2.5. Legal landscape
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Investment & Funding
    • 3.3.5. Merger & Acquisition Analysis

Chapter 4. Molecular Format Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. T-Cell Engager Market: Molecular Format Movement Analysis
  • 4.3. Bispecific T-Cell Engagers
    • 4.3.1. Bispecific T-Cell Engagers Market, 2021-2033 (USD Million)
  • 4.4. TCR-Based T-Cell Engagers
    • 4.4.1. TCR-Based T-Cell Engagers Market, 2021-2033 (USD Million)

Chapter 5. Target Antigen Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. T-Cell Engager Market: Target Antigen Movement Analysis
  • 5.3. CD19
    • 5.3.1. CD19 Market, 2021-2033 (USD Million)
  • 5.4. CD20
    • 5.4.1. CD20 Market, 2021-2033 (USD Million)
  • 5.5. BCMA
    • 5.5.1. BCMA Market, 2021-2033 (USD Million)
  • 5.6. GPRC5D
    • 5.6.1. GPRC5D Market, 2021-2033 (USD Million)
  • 5.7. DLL3
    • 5.7.1. DLL3 Market, 2021-2033 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2021-2033 (USD Million)

Chapter 6. Therapeutic Application Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. T-Cell Engager Market: Therapeutic Application Movement Analysis
  • 6.3. Hematological Malignancies
    • 6.3.1. Hematological Malignancies Market, 2021-2033 (USD Million)
  • 6.4. Solid Tumors
    • 6.4.1. Solid Tumors Market, 2021-2033 (USD Million)
    • 6.4.2. Small Cell Lung Cancer
      • 6.4.2.1. Small Cell Lung Cancer Market, 2021-2033 (USD Million)
    • 6.4.3. Melanoma
      • 6.4.3.1. Melanoma Market, 2021-2033 (USD Million)
    • 6.4.4. Other Solid Tumors
      • 6.4.4.1. Other Solid Tumors Market, 2021-2033 (USD Million)

Chapter 7. Route of Administration Business Analysis

  • 7.1. Segment Dashboard
  • 7.2. T-Cell Engager Market: Route of Administration Movement Analysis
  • 7.3. Intravenous
    • 7.3.1. Intravenous Market, 2021-2033 (USD Million)
  • 7.4. Subcutaneous
    • 7.4.1. Subcutaneous Market, 2021-2033 (USD Million)
  • 7.5. Other (Intraperitoneal)
    • 7.5.1. Other (Intraperitoneal) Market, 2021-2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. T-Cell Engager Market Share By Region, 2025 & 2033
  • 8.2. North America
    • 8.2.1. North America T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Competitive Scenario
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. U.S. T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Competitive Scenario
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Canada T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Competitive Scenario
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Mexico T-Cell Engager Market, 2021-2033 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. UK T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Germany T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. France T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Italy T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Spain T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Denmark T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Sweden T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Norway T-Cell Engager Market, 2021-2033 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Japan T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. China T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. India T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Australia T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Thailand T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.4.7. South Korea
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. South Korea T-Cell Engager Market, 2021-2033 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Brazil T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Argentina T-Cell Engager Market, 2021-2033 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. South Africa T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Saudi Arabia T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. UAE T-Cell Engager Market, 2021-2033 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Kuwait T-Cell Engager Market, 2021-2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Share/ Position Analysis, 2025
  • 9.3. Strategy Mapping
  • 9.4. Company Profiles/Listing
    • 9.4.1. Amgen Inc.
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. F. Hoffmann-La Roche Ltd
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Johnson & Johnson
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Pfizer Inc.
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. AbbVie Inc.
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Genmab A/S
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Regeneron Pharmaceuticals Inc.
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. Immunocore Holdings plc.
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. LINDIS BIOTECH
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Atnahs Pharma Netherlands B.V.
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives
    • 9.4.11. Astellas Pharma Inc.
      • 9.4.11.1. Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product Benchmarking
      • 9.4.11.4. Strategic Initiatives
    • 9.4.12. AstraZeneca
      • 9.4.12.1. Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product Benchmarking
      • 9.4.12.4. Strategic Initiatives
    • 9.4.13. Innovent
      • 9.4.13.1. Overview
      • 9.4.13.2. Financial Performance
      • 9.4.13.3. Product Benchmarking
      • 9.4.13.4. Strategic Initiatives
    • 9.4.14. Wuhan YZY Biopharma Co., Ltd.
      • 9.4.14.1. Overview
      • 9.4.14.2. Financial Performance
      • 9.4.14.3. Product Benchmarking
      • 9.4.14.4. Strategic Initiatives
    • 9.4.15. Xencor
      • 9.4.15.1. Overview
      • 9.4.15.2. Financial Performance
      • 9.4.15.3. Product Benchmarking
      • 9.4.15.4. Strategic Initiatives
Product Code: GVR-4-68041-069-3

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 4 Global T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 5 Global T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 6 Global T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 7 Global T-cell engager market, by region, 2021-2033 (USD million)
  • Table 8 North America T-cell engager market, by country, 2021-2033 (USD million)
  • Table 9 North America T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 10 North America T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 11 North America T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 12 North America T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 13 U.S. T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 14 U.S. T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 15 U.S. T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 16 U.S. T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 17 Canada T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 18 Canada T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 19 Canada T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 20 Canada T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 21 Mexico T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 22 Mexico T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 23 Mexico T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 24 Mexico T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 25 Europe T-cell engager market, by country, 2021-2033 (USD million)
  • Table 26 Europe T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 27 Europe T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 28 Europe T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 29 Europe T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 30 UK T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 31 UK T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 32 UK T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 33 UK T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 34 Germany T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 35 Germany T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 36 Germany T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 37 Germany T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 38 France T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 39 France T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 40 France T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 41 France T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 42 Italy T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 43 Italy T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 44 Italy T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 45 Italy T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 46 Spain T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 47 Spain T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 48 Spain T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 49 Spain T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 50 Denmark T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 51 Denmark T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 52 Denmark T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 53 Denmark T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 54 Sweden T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 55 Sweden T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 56 Sweden T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 57 Sweden T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 58 Norway T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 59 Norway T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 60 Norway T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 61 Norway T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 62 Asia Pacific T-cell engager market, by country, 2021-2033 (USD million)
  • Table 63 Asia Pacific T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 64 Asia Pacific T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 65 Asia Pacific T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 66 Asia Pacific T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 67 Japan T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 68 Japan T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 69 Japan T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 70 Japan T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 71 China T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 72 China T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 73 China T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 74 China T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 75 India T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 76 India T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 77 India T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 78 India T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 79 Australia T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 80 Australia T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 81 Australia T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 82 Australia T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 83 Thailand T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 84 Thailand T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 85 Thailand T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 86 Thailand T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 87 South Korea T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 88 South Korea T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 89 South Korea T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 90 South Korea T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 91 Latin America T-cell engager market, by country, 2021-2033 (USD million)
  • Table 92 Latin America T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 93 Latin America T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 94 Latin America T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 95 Latin America T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 96 Brazil T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 97 Brazil T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 98 Brazil T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 99 Brazil T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 100 Argentina T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 101 Argentina T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 102 Argentina T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 103 Argentina T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 104 Middle East & Africa T-cell engager market, by country, 2021-2033 (USD million)
  • Table 105 Middle East & Africa T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 106 Middle East & Africa T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 107 Middle East & Africa T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 108 Middle East & Africa T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 109 South Africa T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 110 South Africa T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 111 South Africa T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 112 South Africa T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 113 Saudi Arabia T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 114 Saudi Arabia T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 115 Saudi Arabia T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 116 Saudi Arabia T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 117 UAE T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 118 UAE T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 119 UAE T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 120 UAE T-cell engager market, by route of administration, 2021-2033 (USD million)
  • Table 121 Kuwait T-cell engager market, by molecular format, 2021-2033 (USD million)
  • Table 122 Kuwait T-cell engager market, by target antigen, 2021-2033 (USD million)
  • Table 123 Kuwait T-cell engager market, by therapeutic application, 2021-2033 (USD million)
  • Table 124 Kuwait T-cell engager market, by route of administration, 2021-2033 (USD million)

List of Figures

  • Fig. 1 T-cell engager market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market outlook
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 T-cell engager market driver analysis
  • Fig. 12 T-cell engager market restraint analysis
  • Fig. 13 T-cell engager market: Porter's five forces analysis
  • Fig. 14 T-cell engager market: PESTLE analysis
  • Fig. 15 T-cell engager market: molecular format outlook and key takeaways
  • Fig. 16 T-cell engager market: molecular format market share analysis
  • Fig. 17 Bispecific T-cell engagers market, 2021 - 2033 (USD million)
  • Fig. 18 TCR-based T-cell engagers market, 2021 - 2033 (USD million)
  • Fig. 19 T-cell engager market: target antigen outlook and key takeaways
  • Fig. 20 T-cell engager market: target antigen market share analysis
  • Fig. 21 CD19 market, 2021 - 2033 (USD million)
  • Fig. 22 CD20 market, 2021 - 2033 (USD million)
  • Fig. 23 BCMA market, 2021 - 2033 (USD million)
  • Fig. 24 GPRC5D market, 2021 - 2033 (USD million)
  • Fig. 25 DLL3 market, 2021 - 2033 (USD million)
  • Fig. 26 Others market, 2021 - 2033 (USD million)
  • Fig. 27 T-cell engager market: therapeutic application outlook and key takeaways
  • Fig. 28 T-cell engager market: therapeutic application market share analysis
  • Fig. 29 Hematological malignancies market, 2021 - 2033 (USD million)
  • Fig. 30 Solid tumors market, 2021 - 2033 (USD million)
  • Fig. 31 Small cell lung cancer market, 2021 - 2033 (USD million)
  • Fig. 32 Melanoma market, 2021 - 2033 (USD million)
  • Fig. 33 Other solid tumors market, 2021 - 2033 (USD million)
  • Fig. 34 T-cell engager market: route of administration outlook and key takeaways
  • Fig. 35 T-cell engager market: route of administration market share analysis
  • Fig. 36 Intravenous market, 2021 - 2033 (USD million)
  • Fig. 37 Subcutaneous market, 2021 - 2033 (USD million)
  • Fig. 38 Other (intraperitoneal) market, 2021 - 2033 (USD million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America T-cell engager market, by country, 2021 -2033 (USD million)
  • Fig. 41 U.S. T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 42 Canada T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 43 Mexico T-cell engager market, 2021 - 2033, (USD million)
  • Fig. 44 Europe T-cell engager market, by country, 2021 -2033 (USD million)
  • Fig. 45 UK T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 46 Germany T-cell engager market, 2021 - 2033, (USD million)
  • Fig. 47 France T-cell engager market, 2021 - 2033, (USD million)
  • Fig. 48 Italy T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 49 Spain T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 50 Denmark T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 51 Sweden T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 52 Norway T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 53 Asia-Pacific T-cell engager market, by country, 2021 -2033 (USD million)
  • Fig. 54 Japan T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 55 China T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 56 India T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 57 Australia T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 58 Thailand T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 59 South Korea T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 60 Latin America T-cell engager market, by country, 2021 -2033 (USD million)
  • Fig. 61 Brazil T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 62 Argentina T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 63 MEA T-cell engager market, by country, 2021 -2033 (USD million)
  • Fig. 64 South Africa T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 65 Saudi Arabia T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 66 UAE T-cell engager market, 2021 - 2033 (USD million)
  • Fig. 67 Kuwait T-cell engager market, 2021 - 2033 (USD million)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!